ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -7 مورد

Acetaminophen (paracetamol), aspirin, and caffeine: Drug information

Acetaminophen (paracetamol), aspirin, and caffeine: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Acetaminophen (paracetamol), aspirin, and caffeine: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Excedrin Extra Strength [OTC];
  • Excedrin Migraine Relief [OTC];
  • Excedrin Migraine [OTC];
  • FT Migraine Relief [OTC];
  • GoodSense Headache Relief [OTC] [DSC];
  • GoodSense Migraine Formula [OTC];
  • Pain Reliever Extra Strength [OTC];
  • Pain Reliever Plus [OTC];
  • Pain-Off [OTC]
Pharmacologic Category
  • Analgesic, Nonopioid
Dosing: Adult

Not e: Acetaminophen-induced hepatotoxicity, which can be life threatening, has been associated with doses >4 g/day. Although doses up to 4 g/day are generally well tolerated (Ref), hepatotoxicity has been reported rarely at this dose limit (Ref). Due to this risk, some experts recommend a lower maximum dose of 3 g/day in adults with normal liver function, particularly when used for longer durations (eg, >7 days) for pain (Ref). Heavy alcohol use, malnutrition, fasting, low body weight, advanced age, febrile illness, select liver disease, and use of drugs that interact with acetaminophen metabolism may increase risk of hepatotoxicity; a lower total daily dose (eg, 2 g/day) or avoidance may be preferred (Ref). When calculating total daily dose, confirm that all sources (eg, prescription, OTCs, combinations) are included.

Migraine, mild to moderate, acute treatment

Migraine, mild to moderate, acute treatment:

Note: Risk of medication-overuse headache may be higher with combination analgesics containing caffeine; limit use to <10 days per month to avoid medication-overuse headache. Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (Ref).

Oral: Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: 2 tablets as a single dose. Maximum: 2 tablets per 24 hours (Ref).

Minor aches and pain

Minor aches and pain: Oral:

Acetaminophen 194 mg/aspirin 227 mg/caffeine 33 mg: Two tablets every 6 hours as needed (maximum: 8 tablets/day).

Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: Two tablets every 6 hours as needed (maximum: 8 tablets/day).

Acetaminophen 260 mg/aspirin 520 mg/caffeine 32.5 mg: Contents of 1 powder packet, placed on tongue or dissolved in water or other liquid, every 6 hours as needed (maximum: 4 powder packets/day).

Acetaminophen 325 mg/aspirin 500 mg/caffeine 65 mg: Contents of 1 powder packet, placed on tongue or dissolved in water or other liquid, every 6 hours as needed (maximum: 4 powder packets/day).

Tension-type headache, treatment

Tension-type headache, treatment (alternative agent) (off label use): Oral: Acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg: Two tablets once every 24 hours (Ref). Note: Limit use to no more than 2 days per week (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing. Unless alternative agents are ineffective and a gastroprotective agent can be administered, avoid short-term scheduled use of aspirin at doses >325 mg/day in combination with corticosteroids, anticoagulants, or antiplatelet agents or chronic use with or without medications that increase risk for bleeding (Ref).

Dosing: Pediatric
Minor aches and pain

Minor aches and pain: Children >12 years and Adolescents: Oral: Refer to adult dosing

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling. See individual agents.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. See individual agents

Adverse Reactions

See individual agents.

Contraindications

OTC labeling: When used for self-medication, do not use with other products containing acetaminophen, if you are allergic to aspirin other pain relievers/fever reducers or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Drug reaction with eosinophilia and systemic symptoms: Potentially serious, sometimes fatal, drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity reactions, has been reported with nonsteroidal anti-inflammatory drugs (NSAIDs). Monitor for signs and symptoms (eg, fever, rash, lymphadenopathy, eosinophilia) in association with other organ system involvement (eg, hepatitis, nephritis, hematological abnormalities, myocarditis, myositis). Early symptoms of hypersensitivity reaction (eg, lymphadenopathy, fever) may occur without rash; discontinue therapy and further evaluate if DRESS is suspected.

• GI effects: Contains aspirin which may cause stomach bleeding. Risk is increased with ulcers or bleeding problems, using other medications containing an NSAID, ethanol use, or using longer than recommended.

• Hepatotoxicity: Severe liver damage may occur if used with other medications that contain acetaminophen. Limit acetaminophen dose from all sources (prescription and OTC) to ≤4 g/day and avoid or limit ethanol to <3 drinks per day.

• Hypersensitivity reactions: Allergic reactions have been reported with acetaminophen and/or aspirin use.

• Skin reactions: Rarely, acetaminophen may cause serious and potentially fatal skin reactions such as acute generalized exanthematous pustulosis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Discontinue treatment if severe skin reactions develop.

Dosage form specific issues:

• Caffeine: Some products may contain an amount of caffeine similar to one cup of coffee; limit the use of other caffeine-containing beverages or foods.

Special populations:

• Older adult: May have increased risk of severe stomach bleeding in patients 60 years and older.

• Pediatric: Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; patients should be instructed to contact their health care provider if these occur.

Other warnings/precautions:

• Appropriate use: Use for 10 or more days per month may cause medication overuse headache.

• Self-medication (OTC use): Notify health care provider prior to use if you have asthma, arthritis, diabetes, gout, heart disease, high blood pressure, kidney disease, liver disease, stomach bleeding or history of heartburn, or are taking a diuretic. Discontinue use and contact health care provider for any of the following: allergic reaction, bloody/black stools, feeling faint, fever that gets worse or lasts more than 3 days, hearing loss, pain that gets worse or last more than 10 days, redness or swelling of painful area, ringing in the ears, stomach pain that does not get better, vomiting blood, or if new symptoms occur. When used for migraine, contact health care provider prior to use if you have never had a migraine before, if this migraine is different than normal, if your first migraine was diagnosed at over 50 years of age, if you have a stiff neck and fever, if your migraine requires bed rest, or if your headache occurred following coughing, bending, exertion, or head injury

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Excedrin Extra Strength: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [contains benzoic acid, disodium edta, fd&c blue #1 (brill blue) aluminum lake, fd&c red #40(allura red ac)aluminum lake, quinoline (d&c yellow #10) aluminum lake]

Excedrin Extra Strength: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [contains benzoic acid, fd&c blue #1 (brilliant blue)]

Excedrin Extra Strength: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [contains benzoic acid, quinoline yellow (d&c yellow #10)]

Excedrin Migraine: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [contains benzoic acid, fd&c blue #1 (brilliant blue)]

Excedrin Migraine Relief: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [contains benzoic acid, fd&c blue #1 (brilliant blue)]

FT Migraine Relief: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [gluten free; contains fd&c blue #1 (brill blue) aluminum lake, saccharin sodium]

GoodSense Headache Relief: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [DSC] [contains corn starch]

GoodSense Migraine Formula: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg [gluten free; contains fd&c blue #1 (brill blue) aluminum lake, saccharin sodium]

Pain Reliever Extra Strength: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg

Pain Reliever Plus: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg

Pain-Off: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Excedrin Extra Strength Oral)

250-250-65 mg (per each): $0.22

Tablets (Excedrin Migraine Oral)

250-250-65 mg (per each): $0.15

Tablets (Excedrin Migraine Relief Oral)

250-250-65 mg (per each): $0.20

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: Administer with food to avoid GI upset. Drink a full glass of water with each dose.

Administration: Pediatric

Oral: May administer with food to avoid GI upset. Drink a full glass of water with each dose.

Use: Labeled Indications

Migraine , mild to moderate, acute treatment: Treatment of migraine.

Pain: Relief of minor aches and pain.

Use: Off-Label: Adult

Tension-type headache, treatment

Medication Safety Issues
Sound-alike/look-alike issues:

Excedrin may be confused with Dexedrine

Older Adult: High-Risk Medication:

Beers Criteria: Aspirin, when used chronically at doses more than 325 mg/day, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). In addition, avoid for short-term scheduled use in combination with oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents unless alternatives are ineffective and patient can receive concomitant gastroprotective agent (Beers Criteria [AGS 2023]).

Pediatric patients: High-risk medication:

KIDs List: Salicylates, when used in pediatric patients <18 years of age with suspicion of viral illness (influenza, chickenpox), are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of Reye syndrome (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).

Other safety concerns:

Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Abrocitinib: Aspirin may increase antiplatelet effects of Abrocitinib. Management: Do not use aspirin at doses greater than 81 mg/day with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. Risk D: Consider Therapy Modification

Acalabrutinib: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Acebrophylline: May increase stimulatory effects of CNS Stimulants. Risk X: Avoid

Adenosine: Caffeine and Caffeine Containing Products may decrease therapeutic effects of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving caffeine; significantly higher adenosine doses or alternative agents may be required. Discontinue caffeine 24 hours in advance of scheduled diagnostic use of adenosine if possible. Risk D: Consider Therapy Modification

Aducanumab: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Agents with Blood Glucose Lowering Effects: Salicylates may increase hypoglycemic effects of Agents with Blood Glucose Lowering Effects. Risk C: Monitor

Ajmaline: Salicylates may increase adverse/toxic effects of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C: Monitor

Alcohol (Ethyl): May increase adverse/toxic effects of Aspirin. Specifically, alcohol may increase the bleeding risk of aspirin. Alcohol (Ethyl) may decrease therapeutic effects of Aspirin. Specifically, alcohol may interfere with the controlled release mechanism of extended release aspirin. Risk C: Monitor

Alcohol (Ethyl): May increase hepatotoxic effects of Acetaminophen. Risk C: Monitor

Alendronate: Aspirin may increase adverse/toxic effects of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased Risk C: Monitor

Amifampridine: Agents With Seizure Threshold Lowering Potential may increase neuroexcitatory and/or seizure-potentiating effects of Amifampridine. Risk C: Monitor

Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Amisulpride (Oral). Specifically, the risk of seizures may be increased. Risk C: Monitor

Ammonium Chloride: May increase serum concentration of Salicylates. Risk C: Monitor

Anagrelide: May increase antiplatelet effects of Aspirin. Risk C: Monitor

Angiotensin-Converting Enzyme Inhibitors: Salicylates may decrease therapeutic effects of Angiotensin-Converting Enzyme Inhibitors. Salicylates may increase nephrotoxic effects of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor

Anticoagulants (Miscellaneous Agents): Aspirin may increase anticoagulant effects of Anticoagulants (Miscellaneous Agents). Risk C: Monitor

Antiplatelet Agents (P2Y12 Inhibitors): Therapeutic Antiplatelets may increase antiplatelet effects of Antiplatelet Agents (P2Y12 Inhibitors). Risk C: Monitor

ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor

ARIPiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Asenapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Atazanavir: May increase serum concentration of UGT1A1 Substrates. Management: Do not use UGT1A1 substrates for which small increases in exposure can cause serious adverse effects together with atazanavir, and use caution with any UGT1A1 substrate, even when small changes in exposure are less likely to cause serious adverse effects. Risk D: Consider Therapy Modification

Atomoxetine: May increase hypertensive effects of Sympathomimetics. Atomoxetine may increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Belumosudil: May increase serum concentration of UGT1A1 Substrates. Management: Avoid coadministration of belumosudil with substrates of UGT1A1 for which minimal concentration increases can cause serious adverse effects. If coadministration is required, dose reductions of the UGT1A1 substrate may be required. Risk D: Consider Therapy Modification

Benperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Benzbromarone: Salicylates may decrease therapeutic effects of Benzbromarone. Risk C: Monitor

Blonanserin: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Blonanserin. Specifically, the risk of seizures may be increased. Risk C: Monitor

Bornaprine: Sympathomimetics may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Brexpiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Brexpiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Broccoli: May decrease serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor

Bromperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Bromperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Bromperidol: Caffeine and Caffeine Containing Products may decrease absorption of Bromperidol. Risk C: Monitor

BuPROPion: May increase neuroexcitatory and/or seizure-potentiating effects of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor

Busulfan: Acetaminophen may increase serum concentration of Busulfan. Risk C: Monitor

Calcium Channel Blockers (Nondihydropyridine): May increase antiplatelet effects of Aspirin. Risk C: Monitor

Cannabinoid-Containing Products: May increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Cannabis: May decrease serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor

Caplacizumab: May increase antiplatelet effects of Therapeutic Antiplatelets. Management: Avoid this combination if possible. If coadministration is required, monitor closely for bleeding. Interrupt caplacizumab if clinically significant bleeding occurs and administer von Willebrand factor concentrate to rapidly correct hemostasis, if needed. Risk D: Consider Therapy Modification

CarBAMazepine: May increase metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage. Risk C: Monitor

Carbonic Anhydrase Inhibitors: Salicylates may increase adverse/toxic effects of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported. Risk D: Consider Therapy Modification

Cariprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Cariprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ChlorproMAZINE. Specifically, the risk of seizures may be increased. Risk C: Monitor

ClomiPRAMINE: May increase antiplatelet effects of Aspirin. Risk C: Monitor

Clothiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

CloZAPine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of CloZAPine. Specifically, the risk of seizures may be increased. Risk C: Monitor

CloZAPine: CYP1A2 Inhibitors (Weak) may increase serum concentration of CloZAPine. Risk C: Monitor

Cocaine (Topical): May increase hypertensive effects of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider Therapy Modification

Collagenase (Systemic): Aspirin may increase adverse/toxic effects of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. Risk C: Monitor

Corticosteroids (Systemic): Salicylates may increase adverse/toxic effects of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. Risk C: Monitor

CYP1A2 Inducers (Moderate): May decrease serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor

CYP1A2 Inhibitors (Moderate): May increase serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor

CYP1A2 Inhibitors (Strong): May increase serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor

Dapsone (Topical): May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Risk C: Monitor

Dasatinib: Acetaminophen may increase hepatotoxic effects of Dasatinib. Dasatinib may increase serum concentration of Acetaminophen. Management: Avoid coadministration of acetaminophen and dasatinib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure. Risk D: Consider Therapy Modification

Deoxycholic Acid: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Desirudin: Therapeutic Antiplatelets may increase anticoagulant effects of Desirudin. Risk C: Monitor

Dexibuprofen: Aspirin may increase adverse/toxic effects of Dexibuprofen. Dexibuprofen may decrease cardioprotective effects of Aspirin. Risk X: Avoid

Dexketoprofen: Salicylates may increase adverse/toxic effects of Dexketoprofen. Dexketoprofen may decrease therapeutic effects of Salicylates. Salicylates may decrease serum concentration of Dexketoprofen. Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction. Risk X: Avoid

Diazoxide Choline: May increase serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk X: Avoid

Dihydralazine: Sympathomimetics may decrease therapeutic effects of Dihydralazine. Risk C: Monitor

Dipyrone: May decrease antiplatelet effects of Aspirin. Management: Use caution and consider avoiding use of dipyrone in patients treated with aspirin for the treatment or prevention of cardiovascular events or stroke. Risk D: Consider Therapy Modification

Direct Oral Anticoagulants (DOACs): Aspirin may increase anticoagulant effects of Direct Oral Anticoagulants (DOACs). Risk C: Monitor

Donanemab: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Doxofylline: Caffeine and Caffeine Containing Products may increase adverse/toxic effects of Doxofylline. Risk X: Avoid

DroPERidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of DroPERidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Esketamine (Injection): May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for elevated heart rate, hypertension, and arrhythmias may be increased. Risk C: Monitor

Esketamine (Nasal): May increase hypertensive effects of CNS Stimulants. Risk C: Monitor

Fezolinetant: CYP1A2 Inhibitors (Weak) may increase serum concentration of Fezolinetant. Risk X: Avoid

Flucloxacillin: May increase adverse/toxic effects of Acetaminophen. Specifically, the risk for high anion gap metabolic acidosis may be increased. Risk C: Monitor

Flupentixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Flupentixol. Specifically, the risk of seizures may be increased. Risk C: Monitor

FluPHENAZine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of FluPHENAZine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Fondaparinux: Aspirin may increase anticoagulant effects of Fondaparinux. Management: Discontinue aspirin prior to fondaparinux therapy, if possible. If co-administration is required use caution and monitor for bleeding. Risk D: Consider Therapy Modification

Formoterol: Caffeine and Caffeine Containing Products may increase adverse/toxic effects of Formoterol. Caffeine and Caffeine Containing Products may increase hypokalemic effects of Formoterol. Risk C: Monitor

Fosphenytoin-Phenytoin: May decrease serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). Risk C: Monitor

Ginkgo Biloba: May increase anticoagulant effects of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba. Risk D: Consider Therapy Modification

Glycoprotein IIb/IIIa Inhibitors: Therapeutic Antiplatelets may increase anticoagulant effects of Glycoprotein IIb/IIIa Inhibitors. Risk C: Monitor

Guanethidine: May increase hypertensive effects of Sympathomimetics. Guanethidine may increase arrhythmogenic effects of Sympathomimetics. Risk C: Monitor

Haloperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Haloperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Heparin: Aspirin may increase anticoagulant effects of Heparin. Risk C: Monitor

Heparins (Low Molecular Weight): Aspirin may increase anticoagulant effects of Heparins (Low Molecular Weight). Risk C: Monitor

Herbal Products with Anticoagulant/Antiplatelet Effects: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Hyaluronidase: Salicylates may decrease therapeutic effects of Hyaluronidase. Risk C: Monitor

Ibritumomab Tiuxetan: Therapeutic Antiplatelets may increase antiplatelet effects of Ibritumomab Tiuxetan. Risk C: Monitor

Ibrutinib: Therapeutic Antiplatelets may increase adverse/toxic effects of Ibrutinib. Specifically, the risks of bleeding and hemorrhage may be increased. Risk C: Monitor

Icosapent Ethyl: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Iloperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Imatinib: Acetaminophen may increase hepatotoxic effects of Imatinib. Risk C: Monitor

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Acetaminophen may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor

Indacaterol: Caffeine and Caffeine Containing Products may increase adverse/toxic effects of Indacaterol. Caffeine and Caffeine Containing Products may increase hypokalemic effects of Indacaterol. Risk C: Monitor

Influenza Virus Vaccine (Live/Attenuated): May increase adverse/toxic effects of Salicylates. Specifically, Reye's syndrome may develop. Risk X: Avoid

Inotersen: Therapeutic Antiplatelets may increase adverse/toxic effects of Inotersen. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Iohexol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Iomeprol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Iopamidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Isoniazid: May increase hepatotoxic effects of Acetaminophen. Isoniazid may increase metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. Risk C: Monitor

Ketorolac (Nasal): May increase adverse/toxic effects of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may decrease cardioprotective effects of Aspirin. Management: Concurrent use of nasal ketorolac with analgesic doses of aspirin is generally not recommended. If using low-dose, cardioprotective aspirin with nasal ketorolac, monitor the patient closely for evidence of adverse GI effects. Risk D: Consider Therapy Modification

Ketorolac (Systemic): May increase adverse/toxic effects of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may decrease cardioprotective effects of Aspirin. Risk X: Avoid

Kratom: May increase adverse/toxic effects of Sympathomimetics. Risk X: Avoid

LamoTRIgine: Acetaminophen may decrease serum concentration of LamoTRIgine. Risk C: Monitor

Landiolol: Sympathomimetics may decrease therapeutic effects of Landiolol. Risk C: Monitor

Lecanemab: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Levothyroxine: May increase therapeutic effects of Sympathomimetics. Sympathomimetics may increase therapeutic effects of Levothyroxine. Levothyroxine may increase adverse/toxic effects of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Risk C: Monitor

Limaprost: May increase adverse/toxic effects of Therapeutic Antiplatelets. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Linezolid: May increase hypertensive effects of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider Therapy Modification

Lipid Emulsion (Fish Oil Based): May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Lithium: Caffeine and Caffeine Containing Products may decrease serum concentration of Lithium. Risk C: Monitor

Local Anesthetics: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor

Loop Diuretics: Salicylates may decrease therapeutic effects of Loop Diuretics. Loop Diuretics may increase serum concentration of Salicylates. Risk C: Monitor

Lorlatinib: May decrease serum concentration of Acetaminophen. Risk C: Monitor

Loxapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Loxapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Lumateperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Lurasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Macimorelin: Coadministration of Aspirin and Macimorelin may alter diagnostic results. Risk X: Avoid

Methotrexate: Salicylates may increase serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. Management: Consider avoiding coadministration of methotrexate and salicylates. If coadministration cannot be avoided, monitor for increased toxic effects of methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. Risk D: Consider Therapy Modification

Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Methotrimeprazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

MetyraPONE: May increase serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite. Risk X: Avoid

MigALAstat: Caffeine and Caffeine Containing Products may decrease serum concentration of MigALAstat. Risk X: Avoid

Miscellaneous Antiplatelets: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Mitapivat: May decrease serum concentration of UGT1A1 Substrates. Risk C: Monitor

Molindone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Multivitamins/Fluoride (with ADE): May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Multivitamins/Minerals (with ADEK, Folate, Iron): May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Multivitamins/Minerals (with AE, No Iron): May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Nicorandil: Aspirin may increase adverse/toxic effects of Nicorandil. Specifically, the risk of gastrointestinal ulceration and hemorrhage may be increased. Risk C: Monitor

Nitric Oxide: May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Aspirin may increase adverse/toxic effects of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Specifically, the risk of gastrointestinal adverse effects may be increased. Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended. While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissible, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding. Risk D: Consider Therapy Modification

Nonsteroidal Anti-Inflammatory Agents (Nonselective): May decrease therapeutic effects of Aspirin. Aspirin may increase adverse/toxic effects of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Specifically, the risk for bleeding may be increased. Aspirin may decrease serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Management: In general, avoid regular, frequent use of NSAIDs with aspirin whenever possible. If combined, monitor for increased bleeding and a reduced cardioprotective effect of aspirin. Risk D: Consider Therapy Modification

Nonsteroidal Anti-Inflammatory Agents (Topical): May increase adverse/toxic effects of Salicylates. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of salicylates and topical NSAIDs is not recommended. If salicylates and topical NSAIDs are coadministered, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities. Risk D: Consider Therapy Modification

Norfloxacin: May increase serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor

Obinutuzumab: Therapeutic Antiplatelets may increase adverse/toxic effects of Obinutuzumab. Specifically, the risk of bleeding may be increased. Management: Consider avoiding coadministration of obinutuzumab and therapeutic antiplatelets, especially during the first cycle of obinutuzumab therapy. Risk D: Consider Therapy Modification

OLANZapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of OLANZapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Olodaterol: Caffeine and Caffeine Containing Products may increase adverse/toxic effects of Olodaterol. Caffeine and Caffeine Containing Products may increase hypokalemic effects of Olodaterol. Risk C: Monitor

Omacetaxine: Aspirin may increase adverse/toxic effects of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL. Risk X: Avoid

Omega-3 Fatty Acids: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Paliperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Pentosan Polysulfate Sodium: Therapeutic Antiplatelets may increase adverse/toxic effects of Pentosan Polysulfate Sodium. Specifically, the risk of hemorrhage may be increased. Risk C: Monitor

Periciazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Perphenazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Perphenazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

PHENobarbital: May increase metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. Risk C: Monitor

Phenylephrine (Systemic): Acetaminophen may increase serum concentration of Phenylephrine (Systemic). Risk C: Monitor

Pimozide: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pimozide. Specifically, the risk of seizures may be increased. Risk C: Monitor

Pipamperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pipamperone. Specifically, the risk of seizures may be increased. Risk X: Avoid

Pipemidic Acid: May increase serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor

Pirtobrutinib: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor

Potassium Phosphate: May increase serum concentration of Salicylates. Risk C: Monitor

PRALAtrexate: Salicylates may increase serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern. Management: Consider avoiding concomitant use of salicylates and pralatrexate. If coadministered, monitor for increased pralatrexate adverse effects. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. Risk D: Consider Therapy Modification

Prilocaine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor for signs of methemoglobinemia when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid use of these agents with prilocaine/lidocaine cream in infants less than 12 months of age. Risk C: Monitor

Primaquine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Primaquine. Specifically, the risk for methemoglobinemia may be increased. Management: Avoid concomitant use of primaquine and other drugs that are associated with methemoglobinemia when possible. If combined, monitor methemoglobin levels closely. Risk D: Consider Therapy Modification

Primidone: May increase metabolism of Acetaminophen. Specifically, formation of the hepatotoxic NAPQI metabolite may be increased. Risk C: Monitor

Probenecid: Salicylates may decrease therapeutic effects of Probenecid. Salicylates may increase serum concentration of Probenecid. Probenecid may increase serum concentration of Salicylates. Risk X: Avoid

Prochlorperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Prochlorperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Promazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Promazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

QUEtiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of QUEtiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Regadenoson: Caffeine and Caffeine Containing Products may decrease vasodilatory effects of Regadenoson. Management: Avoid use of caffeine and caffeine-containing products for at least 12 hours prior to regadenoson administration. Risk D: Consider Therapy Modification

RifAMPin: May increase hepatotoxic effects of Acetaminophen. RifAMPin may decrease serum concentration of Acetaminophen. Risk C: Monitor

RisperiDONE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of RisperiDONE. Specifically, the risk of seizures may be increased. Risk C: Monitor

Salicylates: May increase anticoagulant effects of Salicylates. Risk C: Monitor

Selective Serotonin Reuptake Inhibitor: May increase antiplatelet effects of Aspirin. Risk C: Monitor

Selumetinib: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Serotonin/Norepinephrine Reuptake Inhibitor: May increase antiplatelet effects of Aspirin. Risk C: Monitor

Sertindole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sertindole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Sincalide: Drugs that Affect Gallbladder Function may decrease therapeutic effects of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider Therapy Modification

Sodium Nitrite: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor

Solriamfetol: CNS Stimulants may increase hypertensive effects of Solriamfetol. CNS Stimulants may increase tachycardic effects of Solriamfetol. Risk C: Monitor

Solriamfetol: Sympathomimetics may increase hypertensive effects of Solriamfetol. Sympathomimetics may increase tachycardic effects of Solriamfetol. Risk C: Monitor

SORAfenib: Acetaminophen may increase hepatotoxic effects of SORAfenib. SORAfenib may increase serum concentration of Acetaminophen. Management: Avoid coadministration of acetaminophen and sorafenib if possible. If coadministration is unavoidable, monitor for signs/symptoms of hepatotoxicity, particularly in patients with greater acetaminophen exposure. Risk D: Consider Therapy Modification

Spironolactone: Aspirin may decrease therapeutic effects of Spironolactone. Risk C: Monitor

Sucroferric Oxyhydroxide: May decrease serum concentration of Aspirin. Management: Administer aspirin at least 1 hour before administration of sucroferric oxyhydroxide. Risk D: Consider Therapy Modification

Sulfinpyrazone: Salicylates may decrease serum concentration of Sulfinpyrazone. Risk X: Avoid

Sulpiride: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sulpiride. Specifically, the risk of seizures may be increased. Risk C: Monitor

Sympathomimetics: May increase adverse/toxic effects of Sympathomimetics. Risk C: Monitor

Talniflumate: Aspirin may increase adverse/toxic effects of Talniflumate. Management: When possible, consider alternatives to this combination. Concurrent use is generally not recommended. Risk D: Consider Therapy Modification

Tedizolid: May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for increased blood pressure and heart rate may be increased. Risk C: Monitor

Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase serum concentration of Theophylline Derivatives. Risk C: Monitor

Thiopental: Aspirin may decrease protein binding of Thiopental. Risk C: Monitor

Thioridazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thioridazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Thiothixene: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Thiothixene. Specifically, the risk of seizures may be increased. Risk C: Monitor

Thrombolytic Agents: Therapeutic Antiplatelets may increase adverse/toxic effects of Thrombolytic Agents. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Ticagrelor: Aspirin may increase antiplatelet effects of Ticagrelor. Aspirin may decrease therapeutic effects of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in adult patients receiving daily aspirin doses greater than 100-150 mg daily. Management: Avoid maintenance aspirin doses greater than 150 mg/day in patients receiving ticagrelor. After any initial dose, only low-dose aspirin (75 to 100 mg/day) is recommended. Risk D: Consider Therapy Modification

Tipranavir: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

TiZANidine: CYP1A2 Inhibitors (Weak) may increase serum concentration of TiZANidine. Management: Avoid the use of tizanidine with weak CYP1A2 inhibitors when possible. If combined, monitor closely for increased tizanidine toxicities (eg, hypotension, bradycardia, drowsiness). Tizanidine dose reduction or discontinuation may be necessary. Risk D: Consider Therapy Modification

Tobacco (Smoked): May decrease serum concentration of Caffeine and Caffeine Containing Products. Risk C: Monitor

Trifluoperazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Trifluoperazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Vaccines: Acetaminophen may decrease therapeutic effects of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination. Risk D: Consider Therapy Modification

Valproic Acid and Derivatives: Salicylates may increase serum concentration of Valproic Acid and Derivatives. Risk C: Monitor

Varicella Virus-Containing Vaccines: Salicylates may increase adverse/toxic effects of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase. Risk X: Avoid

Vitamin E (Systemic): May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Vitamin K Antagonists: Acetaminophen may increase anticoagulant effects of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days. Risk C: Monitor

Vitamin K Antagonists: Aspirin may increase anticoagulant effects of Vitamin K Antagonists. Risk C: Monitor

Volanesorsen: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Warfarin: Caffeine and Caffeine Containing Products may decrease anticoagulant effects of Warfarin. Risk C: Monitor

Zanubrutinib: May increase antiplatelet effects of Therapeutic Antiplatelets. Risk C: Monitor

Ziprasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Ziprasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Zuclopenthixol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Pregnancy Considerations

Refer to individual monographs.

Breastfeeding Considerations

Refer to individual monographs.

Dietary Considerations

Goody's Extra Strength Headache powder contains potassium 60 mg per powder.

Vanquish caplets contain magnesium 20 mg.

Pharmacokinetics (Adult Data Unless Noted)

See individual agents.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Excedrin | Excedrin extra strength | Panadol migraine;
  • (AR) Argentina: Bio electro | Bisolvon gripe | Excedrin | Matrix migra;
  • (AT) Austria: Dolomo | Duan | Excedrinil | Influass | Neuralgin schmerztabletten | Ratiopyrin | Thomapyrin;
  • (BE) Belgium: Excedryn | Perdolan compositum | Troc;
  • (BF) Burkina Faso: Denkalgin;
  • (BG) Bulgaria: Excedrin | Neuralgin;
  • (BR) Brazil: Cibalena a;
  • (CH) Switzerland: Melabon n;
  • (CL) Chile: Prefem | Sevedol | Trigesico;
  • (CN) China: Aspirin compound | Aspirin paracetamol caffeine | Aspirin,paracetamol and caffeine | Compound aspirin | Compound paracetamol | Paracetamol caffeine and aspirin | Paracetamol, caffeine and aspirin | Paracetamol.aspirin and caffeine | Pediatric paracetamol, aspirin and caffeine | Pei bi jia | Xin kang si da;
  • (CO) Colombia: Dolpirin extra fuerte | Excedrin | Sevedol | Tomapyrina;
  • (CZ) Czech Republic: Acifein | Excedrinil | Migralgin | Thomapyrin | Tomapyrin;
  • (DE) Germany: Alacetan | Boxonal | Boxonal n | Cc forte | Chephapyrin n | Dolopyrin al | Doloversa | Excedrin | Fineural N | HA N gegen Schmerzen | Ha tabletten n | Heilit | Herbin stodin | Melabon k | Mindelheimer Kopfschmerz | Mipyrin | Neuradolor | Neuralgin | Neuranidal | Neuranidal n | Novo petrin novum | Ratiopyrin | Schmerztabletten | Spalt plus coffein | Stodinal | Thomapyrin | Thomapyrin classic | Thomapyrin intensiv;
  • (DO) Dominican Republic: Dolocef;
  • (EC) Ecuador: Dolipast | Kronafen plus | Sevedol;
  • (EG) Egypt: Askine | Aspicure combi | Excedrin | Markadel | Pandarin;
  • (ES) Spain: Cerebrino | Neocibalena;
  • (ET) Ethiopia: Aspirin, paracetamol and caffeine;
  • (FR) France: Excedrinil;
  • (GB) United Kingdom: Anadin extra | Asda extra power pain reliever tablets | Dual action pain control | Extra power pain reliever;
  • (GH) Ghana: Efpac | Tarzan;
  • (GR) Greece: Algon | Panmigran | Splentir;
  • (HK) Hong Kong: Chephapyrin n;
  • (ID) Indonesia: Excedrin | Mixanal | Nogren | Poldan MIG;
  • (IE) Ireland: Anadin extra | Excedrin;
  • (IL) Israel: Acamol Focus;
  • (IN) India: Ajubi | Apc | Canid | Decil | Kaparin | Sarbyna-strong;
  • (IT) Italy: Antireumina | Drin | Murri Antidolorifico | Neo cibalgina | Neo nevral | Neo nisidina | Verdal;
  • (JO) Jordan: Cafimol | Excedrin | Pandarin;
  • (KE) Kenya: A.p.c. | Action | Apycy | Aspec | Compral | Dawanol | Hedapan | Hedex | Hedon | Homadex | Kaluma strong | Mara moja | Nexamol | Pharmadex | Poldan MIG | Raha moja | Safimoja | Sona moja | Sonadex | Unimoja;
  • (KR) Korea, Republic of: Acadrin | Free seven | Genset;
  • (LB) Lebanon: Excedrin | Extra strength headache relief | Panadol migraine;
  • (LT) Lithuania: Acifein | Askofenas l | Citramon | Citramon l | Citramon p | Citramon phs | Citramonas L | Thomapyrin;
  • (LU) Luxembourg: Excedryn;
  • (LV) Latvia: Acifein | Ascophen p | Citramon p | Ol-citramons | Thomapyrin;
  • (MX) Mexico: Bio electro | Brepuxene | Excedrin | Tomapirina | Tomapirina es;
  • (NG) Nigeria: Apc plus;
  • (NL) Netherlands: A.pa.c | Apc | Excedrin | Roter apc;
  • (NO) Norway: Paralen;
  • (PE) Peru: Bio electro | Cb zadol | Cefadol | Everdrin forte | Excedrin | Excedrin migrana | Migralivia | Migralud | Migramycin forte | Migrapac | Panaflam Migrana | Sevedol | Tapsin migraine;
  • (PH) Philippines: Saridon;
  • (PK) Pakistan: Adalgin | Analgin | Aspamol | Aspirin comp | Donamol plus | Empirin comp | Excedrin extra strength | Iodopyrin | Mediprin | Nopain | Paxfin | Schazopyrin | Trigesic;
  • (PL) Poland: Apap migrena | Etopiryna extra | Excedrin migrastop | Neopyrin asa | Panpiryna | Paranalgin | Thomapyrin | Tomapyrin;
  • (PR) Puerto Rico: Bayer migraine | Excedrin extra strength | Excedrin menstrual complete | Excedrin migraine | Pain reliever plus;
  • (PT) Portugal: Bisolgrip t;
  • (PY) Paraguay: Calmol;
  • (QA) Qatar: Panadol Migraine;
  • (RO) Romania: Antinevralgic p | Ephimigrin | Excedrinil | Nevralgio;
  • (RU) Russian Federation: Acepar | Algon | Ascofen P | Ascofen plus | Ascophen ultra | Askofen P | Askofen ultra | Citramax forte | Citramon | Citramon akri | Citramon lekt | Citramon mff | Citramon p | Citramon p forte | Citramon ultra | Coficil plus | Excedrin | Iralgesic | Migrenol extra | Neuralgin | Parascofen | Thomapyrin;
  • (SI) Slovenia: Apc | Fenalgin;
  • (SK) Slovakia: Acifein | Excedrin | Migralgin | Thomapyrin;
  • (SR) Suriname: Denkalgin;
  • (TR) Turkey: Excedrin | Paranox triple | Thomapyrin;
  • (TW) Taiwan: A.a.c. | Bo-codein | Bufferin advance | Teiria;
  • (UA) Ukraine: Ascofen | Ascopar | Askophen l | Citramon | Citramon darnitsa | Citramon maxi | Citramonum u | Euro citramon | Farmadol | Thomapyrin | Troychatca;
  • (UG) Uganda: Action tablets | Aspec | Aspec extra | Compral | Headaid | Hedex | Hedon | Hedon plus | Hedon tablets | Mara moja | Painex | Poldan MIG | Rapidex;
  • (VE) Venezuela, Bolivarian Republic of: Mepadol;
  • (ZA) South Africa: Compral | Compral children's size | Grandpa;
  • (ZM) Zambia: Action | Dawanol | Forache | Grandpa
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153 [PubMed 34160823]
  3. Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf. 2007;6(4):341-355. doi: 10.1517/14740338.6.4.341 [PubMed 17688378]
  4. Anacin Advanced Headache Formula (acetaminophen, aspirin, caffeine) [prescribing information]. Langhorne, PA: Insight Pharmaceuticals; no date.
  5. Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol. 2010;17(11):1318-1325. [PubMed 20482606]
  6. Caldeira D, Costa J, Barra M, Pinto FJ, Ferreira JJ. How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. Thromb Res. 2015;135(1):58-61. [PubMed 25456003]
  7. Chou R. Management of subacute and chronic low back pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 3, 2021.
  8. Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy. 2007;27(9):1219-1230. doi:10.1592/phco.27.9.1219 [PubMed 17723075]
  9. Diener HC, Gold M, Hagen M. Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension-type headache: meta-analysis of four randomized, double-blind, placebo-controlled, crossover studies. J Headache Pain. 2014;15:76. [PubMed 25406671]
  10. Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache. 2006;46(suppl 4):S202-S211. doi:10.1111/j.1526-4610.2006.00604.x [PubMed 17078852]
  11. Excedrin Migraine Relief (acetaminophen, aspirin, caffeine) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; received May 2023.
  12. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005;45(8):973-982. doi:10.1111/j.1526-4610.2005.05177.x [PubMed 16109110]
  13. Hamilton JP, Goldberg E, Chopra S. Management of pain in patients with advanced chronic liver disease or cirrhosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 2, 2021.
  14. Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment? Br J Clin Pharmacol. 2016;81(2):210-222. doi:10.1111/bcp.12802 [PubMed 26460177]
  15. Krenzelok EP, Royal MA. Confusion: acetaminophen dosing changes based on NO evidence in adults. Drugs R D. 2012;12(2):45-48. doi:10.2165/11633010-000000000-00000 [PubMed 22530736]
  16. Kwan D, Bartle WR, Walker SE. The Effects of Acetaminophen on Pharmacokinetics and Pharmacodynamics of Warfarin. J Clin Pharmacol. 1999;39(1):68-75. [PubMed 9987702]
  17. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11(3):525-548. doi:10.1016/j.cld.2007.06.006 [PubMed 17723918]
  18. Lee WM, "Drug-Induced Hepatotoxicity," N Engl J Med, 1995, 333(17):1118-27. [PubMed 7565951]
  19. Loder E, Weizenbaum E, Frishberg B, Silberstein S; American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. Headache. 2013;53(10):1651-1659. [PubMed 24266337]
  20. McClain CJ, Price S, Barve S, et al. Acetaminophen Hepatotoxicity: An Update. Curr Gastroenterol Rep. 1999;1(1):42-49. [PubMed 10980926]
  21. Mehlisch DR, Aspley S, Daniels SE, et al. Comparison of the Analgesic Efficacy of Concurrent Ibuprofen and Paracetamol With Ibuprofen or Paracetamol Alone in the Management of Moderate to Severe Acute Postoperative Dental Pain in Adolescents and Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose, Two-Center, Modified Factorial Study. Clin Ther. 2010;32(5):882-895. [PubMed 20685496]
  22. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191. [PubMed 32265601]
  23. Migliardi JR, Armellino JJ, Friedman M, Gillings DB, Beaver WT. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther. 1994;56(5):576-586. [PubMed 7955822]
  24. Refer to manufacturer's labeling.
  25. Shek KL, Chan LN, Nutescu E. Warfarin-Acetaminophen Drug Interaction Revisited. Pharmacotherapy. 1999;19(10):1153-1158. [PubMed 10512064]
  26. Tanaka E, Yamazaki K, Misawa S. Update: The Clinical Importance of Acetaminophen Hepatotoxicity in Nonalcoholic and Alcoholic Subjects. J Clin Pharm Ther. 2000;25(5):325-332. [PubMed 11123483]
  27. Temple AR, Benson GD, Zinsenheim JR, Schweinle JE. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006;28(2):222-235. doi:10.1016/j.clinthera.2006.02.004 [PubMed 16678643]
  28. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272(23):1845-1850. doi:10.1001/jama.1994.03520230055038 [PubMed 7990219]
Topic 9192 Version 428.0